Fiscal Year 2025
(April 1, 2025 to March 31, 2026)

Supplementary Materials
(Consolidated IFRS)

ONO PHARMACEUTICAL CO., LTD.

Contents

【Fiscal Year 2025 (April 1, 2025 to March 31, 2026) Consolidated Financial Results (Core basis)】

Note: “(Billions of yen)” are rounded.

Consolidated Financial Results for FY 2025 (April 1, 2025, to March 31, 2026) (Core basis)

Consolidated Financial Results (Billions of yen)

	FY 2024 (April 1 2024 to March 31, 2025)	FY 2025 (April 1 2025 to March 31, 2026)	YoY
Revenue	486.9	**515.8**	5.9%
Core operating profit	112.7	**137.1**	21.7%
Core profit for the year (attributable to owners of the Company)	90.4	**103.5**	14.5%

Note: The business of the Company and its affiliates consists of a single segment, the pharmaceutical business.

Summary of Consolidated Financial Results for FY 2025 (April 1, 2025, to March 31, 2026) (Core basis)

1. Revenue ¥515.8 billion YoY an increase of 5.9% (FY 2024 ¥486.9 billion)

<Sales of Domestic Products>

- Sales of domestic products totaled ¥281.4 billion, which was a decrease of ¥10.3 billion (3.5%) year on year.
- Sales of Opdivo Intravenous Infusion for malignant tumors decreased by ¥6.0 billion (5.0%) year on year to ¥114.3 billion, mainly due to the intensified competitive environment. Sales of Forxiga Tablets for diabetes, chronic heart failure and chronic kidney disease decreased by ¥1.4 billion (1.5%) year on year to ¥88.2 billion, mainly due to the entry of generic products in December 2025.
- With respect to other main products, sales of Orencia Subcutaneous Injection for rheumatoid arthritis were ¥26.6 billion (0.0% decrease year on year). Sales of Glactiv Tablets for type-2 diabetes were ¥13.2 billion (27.9% decrease year on year). Sales of Velexbru Tablets for malignant tumors were ¥11.9 billion (12.8% increase year on year). Sales of Ongentys Tablets for Parkinson's disease were ¥9.0 billion (17.3% increase year on year). Sales of Parsabiv Intravenous Injection for Dialysis for secondary hyperparathyroidism on hemodialysis were ¥9.0 billion (6.6% increase year on year). Sales of Kyprolis for Intravenous Infusion for multiple myeloma were ¥7.5 billion (12.9% decrease year on year). Sales of Braftovi Capsules for malignant tumors were ¥5.6 billion (33.8% increase year on year).

<Sales of Overseas Products>

- Sales of overseas products totaled ¥61.2 billion, which was an increase of ¥22.1 billion (56.5%) year on year.
- Sales of QINLOCK® (ripretinib) for gastrointestinal stromal tumor, marketed by Deciphera Pharmaceuticals, LLC, the operating company of Deciphera Pharmaceuticals, Inc., increased by ¥12.9 billion (50.6%) year on year (the previous period included only nine months of sales from July to March) to ¥38.4 billion. Additionally, sales of ROMVIMZA(R) (vimseltinib), also marketed by Deciphera, for tenosynovial giant cell tumor (TGCT) treatment were ¥8.3 billion.

<Royalty and Others>

- Royalty and others increased by ¥17.1 billion (10.9%) year on year to ¥173.2 billion, mainly due to an increase in royalty revenue from Bristol-Myers Squibb Company.

2. Core operating profit ¥ 137.1 billion YoY an increase of 21.7 % (FY 2024 ¥ 112.7 billion)

- Core operating profit was ¥137.1 billion, an increase of ¥24.5 billion (21.7%) year on year.
- Cost of sales was ¥107.0 billion, roughly unchanged from the corresponding period of the previous fiscal year.
- Research and development costs increased by ¥1.8 billion (1.2%) year on year to ¥145.1 billion mainly due to the inclusion of research and development expenses from Deciphera Pharmaceuticals, LLC (the previous period accounted for only nine months of Deciphera's expenses (July to March), whereas the current period includes twelve months (April to March)), despite a decrease in research costs.
- Selling, general, and administrative expenses (except for research and development costs) increased by ¥1.4 billion (1.1%) year on year to ¥123.6 billion mainly due to the inclusion of business operating costs from Deciphera Pharmaceuticals, LLC (the previous period accounted for only nine months of Deciphera's expenses (July to March), whereas the current period includes twelve months (April to March)), despite ongoing efforts to improve cost efficiency.

3. Core profit for the year ¥ 103.5 billion YoY an increase of 14.5 % (FY 2024 ¥ 90.4 billion) (attributable to owners of the Company)

- Core profit attributable to owners of the Company increased by ¥13.1 billion (14.5%) year on year to ¥103.5 billion.

Sales Revenue of Major Products

(Billions of yen)

Product Name	FY 2025 (April 1, 2025 to March 31, 2026) Cumulative					YoY		Forecast
	Apr ~ Jun	Jul ~ Sep	Oct ~ Dec	Jan ~ Mar		Change	Change (%)	
<Domestic>								
Opdivo Intravenous Infusion	29.4	29.1	30.6	25.1	**114.3**	(6.0)	(5.0%)	**120.0**
Forxiga Tablets	25.1	23.7	23.9	15.6	**88.2**	(1.4)	(1.5%)	**80.0**
Orencia for Subcutaneous Injection	7.0	6.8	7.2	5.6	**26.6**	(0)	(0.0%)	**28.0**
Glactiv Tablets	3.6	3.4	3.5	2.8	**13.2**	(5.1)	(27.9%)	**12.0**
Velexbru Tablets	3.0	3.0	3.2	2.7	**11.9**	1.4	12.8%	**11.0**
Ongentys Tablets	2.3	2.2	2.5	2.0	**9.0**	1.3	17.3%	**9.0**
Parsabiv Intravenous Injection	2.2	2.3	2.5	2.1	**9.0**	0.6	6.6%	**9.0**
Kyprolis for Intravenous Infusion	2.0	2.0	2.0	1.5	**7.5**	(1.1)	(12.9%)	**9.0**
Braftovi Capsules	1.3	1.4	1.5	1.5	**5.6**	1.4	33.8%	**–**
<Overseas>								
Opdivo	3.3	3.9	3.6	3.4	**14.2**	1.0	8.0%	**13.5**
QINLOCK	8.9	9.2	10.5	9.7	**38.4**	12.9	50.6%	**36.0**
ROMVIMZA™	1.1	1.7	2.6	2.9	**8.3**	–	–	**8.0**

Notes: 1. Sales revenue of domestic products is shown in a gross sales basis (shipment price).
2. Sales revenue of overseas products is shown in a net sales basis.

Details of Sales Revenue

(Billions of yen)

	FY 2024 (April 1, 2024 to March 31, 2025)	**FY 2025 (April 1, 2025 to March 31, 2026)**
Revenue of goods and products	330.8	**342.6**
Royalty and others	156.1	**173.2**
Total	486.9	**515.8**

Note: In "Royalty and others", royalty revenue of Opdivo from Bristol-Myers Squibb Company is included, which is ¥113.0 billion for the fiscal year ended March 31, 2025, and ¥122.3 billion for the fiscal year ended March 31, 2026. Royalty revenue of Keytruda® from Merck & Co., Inc. is included, which is ¥26.4 billion for the fiscal year ended March 31, 2025, and ¥29.5 billion for the fiscal year ended March 31, 2026.

Revenue by Geographic Area

(Billions of yen)

	FY 2024 (April 1, 2024 to March 31, 2025)	**FY 2025 (April 1, 2025 to March 31, 2026)**
Japan	295.2	**287.1**
Americas	167.0	**197.1**
Asia	16.3	**17.7**
Europe	7.5	**12.3**
Others	0.7	**1.6**
Total	486.9	**515.8**

Note: Revenue by geographic area is presented on the basis of the place of customers.

Reconciliation from Full to Core basis for the FY 2025 (April 1, 2025 to March 31, 2026)

<Definition of core basis>
Core financial results are calculated by deducting items that are not inherently related to the company's business performance or are one-time occurrences from the IFRS-based financial results. Adjustment items include amortization expenses arising from intangible assets acquired through acquisitions or in-licensing, impairment losses, compensation or settlement costs from litigation, and losses due to disasters.

(Billions of Yen)

	IFRS (Full) basis	Amortization	Impairment loss	Others	Core basis
Sales revenue	**515.8**				**515.8**
Cost of sales	**(141.7)**	25.6		9.1	**(107.0)**
Gross profit	**374.1**	25.6		9.1	**408.7**
SG&A expenses	**(123.7)**			0.1	**(123.6)**
R&D costs	**(147.0)**		1.9		**(145.1)**
Other income	**0.9**			(0.2)	**0.7**
Other expenses	**(12.0)**		0.2	8.2	**(3.6)**
Operating profit	**92.2**	25.6	2.1	17.2	**137.1**
Operating profit ratio	**17.9%**				**26.6%**
Finance income	**4.0**			(0.2)	**3.7**
Finance costs	**(3.5)**			0.9	**(2.6)**
Profit before tax	**92.7**	25.6	2.1	17.9	**138.3**
Income tax	**(22.7)**	(6.5)	(0.6)	(4.8)	**(34.6)**
Profit for the year	**69.9**	19.2	1.5	13.1	**103.6**
Non-controlling	**0.1**				**(0.1)**
Profit for the year (Attributable to owners of the company)	**69.8**	19.2	1.5	13.1	**103.5**

Cost of sales – "Other" includes the cost of inventory that was measured at fair value and expensed in connection with the acquisition of Deciphera.
Other expenses – "Other" mainly include the following items:
- A loss of ¥4.3 billion representing the difference between the consideration received for the transfer of selling rights following the termination of the co-promotion agreement with AstraZeneca and the decrease in the carrying amount of the selling rights for Forxiga Tablets.
- A loss of ¥1.7 billion arising from amendments to the retirement benefit plan due to the transition to a defined contribution pension plan.
- A loss of ¥1.4 billion on product recall costs related to certain products.

Consolidated Financial Forecast for FY 2026 (April 1, 2026, to March 31, 2027) (Core Basis)

Consolidated Financial Forecast

(Billions of Yen)

	FY 2024 (April 1, 2024 to March 31, 2025)	FY 2025 (April 1, 2025 to March 31, 2026)	**FY 2026 (April 1, 2026 to March 31, 2027)**	YoY
Revenue	486.9	515.8	**455.0**	(11.8)%
Core operating profit	112.7	137.1	**124.0**	(9.6)%
Core profit for the year (attributable to owners of the Company)	90.4	103.5	**93.0**	(10.1)%

Summary of Consolidated Financial Forecast for FY 2026 (April 1, 2026, to March 31, 2027) (Core basis)

1. Revenue ¥455.0 billion YoY a decrease of ¥60.8 billion (11.8%)

- Revenue of goods and products are expected to be ¥270.0 billion, a decrease of ¥72.6 billion (21.2%) year on year, mainly due to the absence of sales of Forxiga Tablets following the termination of the co-promotion agreement with AstraZeneca, despite continued growth in prescriptions of Opdivo Intravenous Infusion, QINLOCK, a treatment for gastrointestinal stromal tumors, and ROMVIMZA, a treatment for tenosynovial giant cell tumor (TGCT).
- Royalty and others are expected to increase by ¥11.8 billion (6.8%) year on year to ¥185.0 billion, mainly due to increased royalty income from Bristol Myers Squibb and other partners.
- Revenue is therefore expected to be ¥455.0 billion, a decrease of ¥60.8 billion (11.8%) year on year.

2. Core Operating profit ¥124.0 billion YoY a decrease of ¥13.1 billion (9.6%)

- Cost of sales is expected to be ¥84.0 billion, a decrease of ¥23.0 billion (21.5%) year on year, mainly due to the decrease in sales following the termination of the co-promotion agreement for Forxiga Tablets.
- Research and development costs are expected to be ¥143.0 billion, a decrease of ¥2.1 billion (1.5%) year on year. The Company will continue proactive R&D investments, exceeding 30% of net sales, including the conduct of global clinical trials for compounds such as sapablursen and ONO-4578.
- Selling, general, and administrative expenses (except for research and development costs) are expected to be ¥101.0 billion, a decrease of ¥22.6 billion (18.3%) year on year, mainly due to a reduction in co-promotion expenses associated with the termination of the co-promotion agreement for Forxiga Tablets.
- Therefore, core operating profit is expected to be ¥124.0 billion, a decrease of ¥13.1 billion (9.6%) year on year.

3. Core profit for the year ¥93.0 billion YoY a decrease of ¥10.5 billion (10.1%) (attributable to owners of the Company)

- Core profit attributable to owners of the Company is expected to be ¥93.0 billion, a decrease of ¥10.5 billion (10.1%) year on year.

Sales Revenue of Major Products (Forecast)

(Billions of yen)

Product Name	FY 2025 (April 1, 2025 to March 31, 2026) Results	YoY Change	YoY Change (%)	**FY 2026 Forecast (April 1, 2026 to March 31, 2027) Forecast**	YoY Change	YoY Change (%)
<Domestic>						
Opdivo Intravenous Infusion	114.3	(6.0)	(5.0%)	120.0	5.7	5.0%
Orencia for Subcutaneous Injection	26.6	(0.0)	(0.0%)	19.0	(7.6)	(28.6%)
Velexbru Tablets	11.9	1.4	12.8%	12.0	0.1	0.9%
Parsabiv Intravenous Injection	9.0	0.6	6.6%	10.0	1.0	11.2%
Ongentys Tablets	9.0	1.3	17.3%	10.0	1.0	11.5%
Glactiv Tablets	13.2	(5.1)	(27.9%)	9.5	(3.7)	(28.1%)
Braftovi Capsules	5.6	1.4	33.8%	8.5	2.9	51.5%
Kyprolis for Intravenous Infusion	7.5	(1.1)	(12.9%)	7.0	(0.5)	(6.6%)
<Overseas>						
Opdivo	14.2	1.0	8.0%	13.0	(1.2)	(8.2%)
QINLOCK	38.4	12.9	50.6%	43.0	4.6	12.1%
ROMVIMZA	8.3	–	–	19.0	10.7	129.4%

Details of Sales Revenue (Forecast)

(Billions of yen)

	FY 2025 (April 1, 2025 to March 31, 2026)	**FY 2026 Forecast (April 1, 2026 to March 31, 2027)**
Revenue of goods and products	342.6	**270.0**
Royalty and others	173.2	**185.0**
Total	515.8	**455.0**

Depreciation and Amortization, Capital Expenditure and Investments on Intangible Assets

Depreciation and Amortization

(Billions of Yen)

	FY 2024 (April 1, 2024 to March 31, 2025)	**FY 2025 (April 1, 2025 to March 31, 2026)**	**FY 2026 Forecast (April 1, 2026 to March 31, 2027)**
Property, plant, and equipment	10.6	**10.6**	**11.0**
Intangible assets	16.3	**27.2**	**25.1**
Total	26.9	**37.8**	**36.2**
Ratio to sales revenue	5.5%	**7.3%**	**8.0%**

Capital Expenditure (Based on Constructions) and Investments on Intangible Assets

(Billions of yen)

	FY 2024 (April 1, 2024 to March 31, 2025)	**FY 2025 (April 1, 2025 to March 31, 2026)**	**FY 2026 Forecast (April 1, 2026 to March 31, 2027)**
Property, plant, and equipment	8.1	**7.9**	**10.2**
Intangible assets	2.6	**47.1**	**6.3**
Total	10.7	**55.0**	**16.5**

Number of Employees (Consolidated)

	FY 2024 (as of March 31, 2025)	**FY 2025 (as of March 31, 2026)**
Number of employees	4,287	**4,206**

Status of Shares (as of March 31, 2026)

Number of Shares

	As of March 31, 2026
Total number of authorized shares	1,500,000,000
Number of shares issued and outstanding	498,692,800

Number of Shareholders

	As of March 31, 2026
Number of shareholders	111,306

Principal Shareholders

(As of March 31, 2026)

Name of shareholder	Number of shares held (Thousands of shares)	Shareholding percentage
The Master Trust Bank of Japan, Ltd. (Trust account)	65,572	13.70
Custody Bank of Japan, Ltd. (Trust account)	25,228	5.27
Meiji Yasuda Life Insurance Company	18,594	3.88
Ono Scholarship Foundation	16,428	3.43
KAKUMEISOU Co., LTD.	16,158	3.37
JP Morgan Securities Japan Co., Ltd	14,869	3.10
MUFG Bank, Ltd.	8,640	1.80
The Master Trust Bank of Japan, Ltd. (Stock Grant ESOP Trust Account 80358)	8,398	1.75
STATE STREET BANK AND TRUST COMPANY 505001	7,298	1.52
BNYM AS AGT/CLTS 10 PERCENT	6,906	1.44

Notes: 1. The Company is excluded from the principal shareholders listed in the table above, although the Company holds 20,387 thousand shares of treasury share.
2. The shareholding percentage is calculated by deducting treasury share (20,387 thousand shares).

Ownership and Distribution of Shares



Note: The ratio by shareholders listed above is rounded down to two decimal places. Therefore, their total does not amount to 100%.

Main Status of Development Pipelines

As of May 8, 2026, we have listed our pipeline, which includes projects that we are developing clinically either independently (including through our wholly-owned subsidiaries) or in collaboration with partners, as well as those for which we hold contractual rights for potential future clinical development and/or commercialization. Please note that this does not encompass all development activities.

- For regions where we have obtained marketing approval for any indication, the product name is also listed.
- The development stage is indicated for the main countries/regions where we hold rights.
- The start date for clinical trials is based on the date of acceptance of the clinical trial notification, unless otherwise specified.
- Regarding in-house/in-license products, those in which the Ono Group was involved in the drug discovery process during joint research are considered in-house, while those for which we hold commercialization rights are considered in-license. For limited rights, the specific countries/regions are listed separately.

(Oncology)

Development code Generic name Product name (Dosage form)	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
ONO-4538 Nivolumab Opdivo (Intravenous injection)	A human anti-human PD-1 monoclonal antibody	Hepatocellular carcinoma, First-line treatment (Combination with Yervoy)	Approved (Japan) 25/06 Approved (South Korea) 25/07 Approved (Taiwan) 25/07	In-house (Co-development with Bristol-Myers Squibb)
		MSI-H/dMMR colorectal cancer, First-line treatment (Combination with Yervoy)	Approved (Japan) 25/08 Approved (Taiwan) 26/01 Approved (South Korea) 26/02	In-house (Co-development with Bristol-Myers Squibb)
		Hepatocellular carcinoma, Adjuvant therapy	P3	In-house (Co-development with Bristol-Myers Squibb)
		Non-small cell lung cancer, Neoadjuvant and adjuvant therapy (Combination with chemotherapy)	P3	In-house (Co-development with Bristol-Myers Squibb)
		Rhabdoid tumor, Second-line treatment	P2	In-house (Co-development with Bristol-Myers Squibb)
		Richter transformation, Second-line treatment	P2	In-house (Co-development with Bristol-Myers Squibb)
ONO-7702 Encorafenib Braftovi (Oral medication)	BRAF inhibitor	Colorectal cancer, First-line treatment, BRAF-mutation (Combination with Cetuximab and chemotherapy (FOLFOX))	Approved (Japan) 25/11 Approved (South Korea) 26/01	In-license (Japan, South Korea) (Pfizer)
ONO-4059 Tirabrutinib Hydrochloride Velexbru (Oral medication)	BTK (Bruton's tyrosine kinase) inhibitor	Primary central nervous system lymphoma, Second-line treatment and beyond	Filed (USA) 25/12	In-house
		Primary central nervous system lymphoma, second-line treatment and beyond	P3	In-house
		Primary central nervous system lymphoma, First-line treatment	P2	In-house
DCC-2618 ripretinib QINLOCK (Oral medication)	KIT inhibitor	Gastrointestinal stromal tumor, Second-line treatment for patients with KIT exon 11+17/18 mutation	P3	In-house
		Gastrointestinal stromal tumor, Fourth-line treatment	Filed (Japan) 26/03, P1	In-house

Development code Generic name Product name (Dosage form)	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
ONO-0530 sapablursen (Subcutaneous injection)	TMPRSS6 gene expression inhibitor (Oligonucleotide)	Polycythemia vera	P3	In-license (Ionis Pharmaceuticals, Inc)
ONO-4578 (Oral medication)	Prostaglandin receptor (EP4) antagonist	Gastric cancer, First-line treatment (Standard treatment (combination with Opdivo and chemotherapy))	P2	In-house
		Colorectal cancer, First-line treatment (combination with Opdivo and standard treatment)	P2	In-house
		Non-small cell lung cancer, Second-line treatment (combination with Opdivo and standard treatment)	P1	In-house
ONO-4482 relatlimab (Intravenous injection)	Anti-LAG-3 antibody	Melanoma, Second-line treatment and beyond (Combination with Opdivo)	P1/2	In-license (Japan, South Korea, Taiwan) (Co-development with Bristol-Myers Squibb)
ONO-7427 (Intravenous injection)	Anti-CCR8 antibody	Solid tumor (Combination with Opdivo)	P1/2	In-license (Japan, South Korea, Taiwan) (Co-development with Bristol-Myers Squibb)
DCC-3116 inlexisertib (Oral medication)	ULK inhibitor	Advanced malignancies (Combination with ripretinib)	P1/2	In-house
DCC-3009 (Oral medication)	Pan-KIT inhibitor	Gastrointestinal stromal tumor	P1/2	In-house
DCC-2812 (Oral medication)	GCN2 activator	Renal cell carcinoma, urothelial carcinoma, castration-resistant prostate cancer	P1	In-house
ONO-4685 Besufetamig (Intravenous injection)	PD-1 x CD3 bispecific antibody	T-cell lymphoma, Second-line treatment	P1	In-house
ONO-4538HSC (Subcutaneous injection)	A human anti-human PD-1monoclonal antibody	Solid tumor	P1	In-license (Japan, South Korea, Taiwan) (Co-development with Bristol-Myers Squibb)
ONO-8250 (Intravenous injection)	iPS cell-derived HER2-targeted CAR-T cell therapeutics	HER2-expressing solid tumors	P1	In-house (Co-development with Fate Therapeutics, Inc.)
ONO-7428 (Intravenous injection)	Anti-ONCOKINE-1 antibody	Solid tumor	P1	In-license (NEX-I, Inc.)
ONO-7429 (Intravenous injection)	Anti-L1CAM ADC	Solid tumor	P1	In-license (LigaChem Biosciences, Inc.)

(Areas Other than Oncology)

Development code Generic name Product name （Dosage form）	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
DCC-3014 vimseltinib ROMVIMZA (Oral medication)	CSF-1R inhibitor	Tenosynovial giant cell tumor	Approved(USA) 25/02 Approved (Europe) 25/09	In-house
		cGvHD	P2	In-house
ONO-2017 Cenobamate (Oral medication)	Inhibition of voltage-gated sodium currents/positive allosteric modulator of $GABA_A$ ion channel	Partial-onset seizures	Filed (Japan) 25/09	In-license (Japan) (SK Biopharmaceuticals)
		Partial-onset seizures (Pediatric)	P3	In-license (Japan) (SK Biopharmaceuticals)
		Primary generalized tonic-clonic seizures	P3	In-license (Japan) (SK Biopharmaceuticals)
ONO-4059 Tirabrutinib hydrochloride Velexbru （Oral medication）	BTK (Bruton's tyrosine kinase) inhibitor	Steroid-resistant pemphigus	P3	In-house
ONO-8531 povetacicept (Subcutaneous injection)	BAFF/APRIL dual antagonist	Immunoglobulin A nephropathy (IgAN)	P3	In-license (Japan, South Korea) (Vertex Pharmaceuticals Incorporated)
		Membranous nephropathy	P2b/3	In-license (Japan, South Korea) (Vertex Pharmaceuticals Incorporated)
ONO-5532 Gel-One (Intra-articular injection)	Cross-linked hyaluronate	Knee osteoarthritis	P3	In-license (Japan) (Seikagaku Corporation)
		Hip osteoarthritis	P3	In-license (Japan) (Seikagaku Corporation)
ONO-2808 (Oral medication)	S1P5 receptor agonist	Multiple system atrophy	P2	In-house
ONO-2020 (Oral medication)	Epigenetic regulation	Alzheimer's disease	P2	In-house
		Agitation associated with dementia due to Alzheimer's disease	P2	In-house
ONO-1110 (Oral medication)	Endocannabinoid regulation	Postherpetic neuralgia	P2	In-house
		Major depressive disorder	P2	In-house
		Fibromyalgia	P2	In-house
		Social anxiety disorder	P2	In-house
		Hunner type interstitial cystitis	P2	In-house
ONO-4685 Besufetamig (Intravenous injection)	PD-1×CD3 bispecific antibody	Autoimmune disease	P1	In-house
ONO-4915 (Intravenous injection /Subcutaneous injection)	PD-1×CD19 bispecific antibody	Autoimmune disease	P1	In-house

Development code Generic name Product name (Dosage form)	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
ONO-2416 (Oral medication)		Psychiatric disorders	P1	In-house
ONO-3310 (Oral medication)		Kidney diseases	P1	In-house
ONO-6414 (Oral medication)		Autoimmune disease	P1	In-house

The change from the announcement of financial results for the Third quarter of the fiscal year ended March 31, 2026, is as follows:

(Oncology)

Development code Generic name Product name (Dosage form)	Pharmacological Action	Target indication (Combination drug)	Development status or reason for termination
ONO-4059 Tirabrutinib Hydrochloride Velexbru (Oral medication)	BTK (Bruton's tyrosine kinase inhibitor)	Primary central nervous system lymphoma, Second-line treatment and beyond	In December 2025, an application of ONO-4059 (BTK inhibitor) was filed in the U.S., for the treatment of recurrent or refractory primary central nervous system lymphoma.
ONO-4538 Nivolumab Opdivo (Intravenous injection)	A human anti-human PD-1 monoclonal antibody	MSI-H/dMMR colorectal cancer, First-line treatment (Combination with Yervoy)	In February 2026, an application of ONO-4538 in combination with Yervoy was approved in South Korea for the treatment of unresectable advanced or recurrent high microsatellite instability (MSI-High) or mismatch repair-deficient (dMMR) colorectal cancer.
ONO-0530 Sapablursen (subcutaneous injection)	TMPRSS6 gene expression inhibitor	Polycythemia vera	In February 2026, an international phase III clinical trial of ONO-0530/sapablursen (TMPRSS6 gene expression inhibitor) was initiated for the treatment of polycythemia vera.
DCC-2618 ripretinib QINLOCK (Oral medication)	KIT inhibitor	Gastrointestinal stromal tumor (GIST) Fourth-line treatment	In March 2026, an application of approval of DCC-2618 (KIT inhibitor) was filed in Japan for the fourth-line treatment of gastrointestinal stromal tumor (GIST), based on the results of global Phase III clinical trials. In addition, phase I of DCC-2618 was initiated in Japan to evaluate the safety and pharmacokinetics of QINLOCK in Japanese patients with GIST.
ONO-4578 (Oral medication)	Prostaglandin EP4 receptor antagonist	Hormone receptor-positive, HER2-negative breast cancer First-line treatment (combination with standard treatment)	In March 2026, Phase I of ONO-4578 (a prostaglandin EP4 receptor antagonist) for the treatment of hormone receptor-positive, HER2-negative breast cancer was conducted, but the project was discontinued due to strategic reasons.
ONO-7429 (Intravenous injection)	Anti-L1CAM ADC	Solid tumor	In March 2026, phase I of ONO-7429 (Anti-L1CAM ADC) was initiated in Japan for the treatment of solid tumor.
ONO-4538 Nivolumab Opdivo (Intravenous Injection)	A human anti-human PD-1 monoclonal antibody	Bladder cancer Adjuvant/neoadjuvant treatment (Combination with chemotherapy)	In April 2026, phase III trial was conducted in Japan in combination therapy of Opdivo and chemotherapy for adjuvant/ neoadjuvant treatment of bladder cancer. However, as the primary endpoint was not met, the development has been discontinued.
ONO-7913 magrolimab (Intravenous Injection)	Anti-CD47 antibody	Pancreatic cancer, First-line treatment (combination with Opdivo) Colorectal cancer First-line treatment (combination with Opdivo)	In April 2026, phase I trial of ONO-7913 (anti-CD47 antibody) was conducted in combination therapy with Opdivo for the treatment of pancreatic cancer and colorectal cancer. However, the development has been discontinued due to strategic reasons.

(Areas Other than Oncology)

Development code Generic name Product name （Dosage form）	Pharmacological Action	Target indication (Combination drug)	Development status or reason for termination
ONO-2017 Cenobamate (Oral medication)	Inhibition of voltage-gated sodium currents/positive allosteric modulator of $GABA_A$ ion channel	Partial-onset seizures (pediatric)	In February 2026, Phase III of ONO-2017 (Inhibition of voltage-gated sodium currents/positive allosteric modulator of $GABA_A$ ion channel) was initiated for the treatment of partial-onset seizures (pediatric).
ONO-8531 povetacicept (Subcutaneous injection)	BAFF/APRIL dual antagonist	Membranous nephropathy	Phase IIb/III of ONO-8531 (BAFF/APRIL dual antagonist) for the treatment of membranous nephropathy has been added to the development pipeline.
ONO-2416 (Oral Medication)		Psychiatric disorders	In February 2026, Phase I of ONO-2416 was initiated in healthy adults in Japan for the treatment of for psychiatric disorders.
ONO-3310 (Oral Medication		Kidney disease	In March 2026, Phase I of ONO-3310 was initiated in Japan for the treatment of kidney diseases.
ONO-6414 (Oral Medication		Autoimmune disease	In April 2026, Phase I of ONO-6414 was initiated in the United States for the treatment of autoimmune diseases.

Profile for Main Development

Opdivo Intravenous Infusion (ONO-4538 / BMS-936558) / Nivolumab (injection)
Opdivo, a human anti-human PD-1 monoclonal antibody, is being developed for the treatment of various kinds of cancers, etc. PD-1 is a receptor expressed on the surface of activated lymphocytes and plays a role in a regulatory pathway that suppresses the activated lymphocytes in the body (negative signal). Research indicates that cancer cells exploit this pathway to escape from immune responses. Opdivo is thought to provide benefit by blocking PD-1-mediated negative regulation of lymphocytes, thereby enhancing the ability of the immune system to recognize cancer cells as foreign and eliminate them.
In Japan, South Korea, and Taiwan, Ono is co-developing this with Bristol-Myers Squibb Company. In the other areas, Bristol-Myers Squibb Company is developing this.

Yervoy Injection (ONO-4480) / Ipilimumab (injection)
Yervoy, a human anti-human CTLA-4 monoclonal antibody, is being developed for the treatment of various kinds of cancer.
In Japan, South Korea, and Taiwan, Ono is co-developing this with Bristol-Myers Squibb Company. In the other areas, Bristol-Myers Squibb Company is developing this.

ONO-4482 / BMS-986016 / relatlimab (injection)
ONO-4482, a human anti-human LAG-3 monoclonal antibody, is being developed for the treatment of melanoma.
In Japan, South Korea, and Taiwan, Ono is co-developing this with Bristol-Myers Squibb Company. In the other areas, Bristol-Myers Squibb Company is developing this.

ONO-4578 (oral)
ONO-4578, a prostaglandin receptor (EP4) antagonist, is being developed for the treatment of gastric cancer, colorectal cancer, and non-small cell lung cancer.

Braftovi Capsules (ONO-7702) / Encorafenib (oral)
Braftovi, a BRAF inhibitor, has been marketed in Japan for the treatment of melanoma, and an additional indication was later approved in Japan for the treatment of BRAF-mutant colorectal cancer. Additionally, we have obtained approval in Japan for the treatment of unresectable BRAF-mutant thyroid cancer and unresectable anaplastic BRAF-mutant thyroid cancer, in combination with Mektovi tablets after progression following cancer chemotherapy. Furthermore, an application was approved in South Korea for the treatment of BRAF-mutant unresectable advanced or recurrent colorectal cancer.

Velexbru Tablets (ONO-4059) / Tirabrutinib Hydrochloride (oral)
Velexbru, a BTK inhibitor, has been marketed in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma, and additional indications were later approved for the treatment of waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma. Additionally, applications were approved in South Korea and Taiwan for the treatment of recurrent or refractory B-cell primary central nervous system lymphoma. Furthermore, an application of approval was filed in the USA for the treatment of primary central nervous system lymphoma. It is also being developed in Japan for the treatment of pemphigus.

ONO-4685 / besufetamig (injection)
ONO-4685, a PD-1 x CD3 bispecific antibody, is being developed for the treatment of autoimmune disease. In the oncology area, it is being developed in Japan and the USA for the treatment of T-cell lymphoma.

ONO-4538HSC (subcutaneous injection)
ONO-4538HSC, a combination drug comprising nivolumab and volhyaluronidase alfa, is being developed in Japan for the treatment of solid tumor.

ONO-8250 (injection)
ONO-8250, an iPS cell-derived HER2-targeted CAR-T cell therapeutics, is being developed in the USA for the treatment of HER2-expressing solid tumor.

ONO-7427 (injection)
ONO-7427, an anti-CCR8 antibody, is being developed in Japan for the treatment of solid tumor.
In Japan, South Korea, and Taiwan, Ono is co-developing this with Bristol-Myers Squibb Company. In the other areas, Bristol-Myers Squibb Company is developing this.

ONO-7428 (injection)
ONO-7428, an anti-ONCOKINE-1 antibody, is being developed in Japan for the treatment of solid tumor.

ONO-0530 / sapablursen (subcutaneous injection)
ONO-0530, an antisense oligonucleotide targeting TMPRSS6, is being developed for the treatment of polycythemia vera.

ONO-2017 / Cenobamate (oral)
An application of ONO-2017, an inhibition of voltage-gated sodium currents / positive allosteric modulator of $GABA_A$ ion channel, for the treatment of partial-onset seizures was filed in Japan. In addition, it is being developed in Japan for the treatment of partial-onset seizures (pediatric) and primary generalized tonic-clonic seizures.

ONO-2808 (oral)
ONO-2808, a S1P5 receptor agonist, is being developed in Japan and the USA for the treatment of multiple system atrophy.

ONO-2020 (oral)
ONO-2020, an epigenetic regulation, is being developed for the treatment of Alzheimer's disease in Japan and the USA, and for the treatment of agitation associated with dementia due to Alzheimer's disease in Japan.

ONO-1110 (oral)

ONO-1110, an endocannabinoid regulation, is being developed in Japan for the treatment of postherpetic neuralgia, major depressive disorder, fibromyalgia, social anxiety disorder, and hunner type interstitial cystitis.

ONO-4915 (injection / subcutaneous injection)

ONO-4915, a PD-1×CD19 bispecific antibody, is being developed in Japan for the treatment of autoimmune disease.

QINLOCK (DCC-2618) / ripretinib (oral)

QINLOCK is a KIT inhibitor that has been approved by the US FDA for the treatment of adult patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with three or more kinase inhibitors, including imatinib. It is based on the favorable results in fourth-line and fourth-line +GIST patients in the Phase 3 INVICTUS trial and has been approved in regions such as North America, Europe, and Australia. In addition, it is being developed as a potential second-line treatment for GIST patients with KIT exon 11+17/18 mutations. Also, an application of approval was filed in Japan for the fourth-line treatment of GIST.

ROMVIMZA (vimseltinib) (oral)

ROMVIMZA (DCC-3014) is a CSF-1R inhibitor that has been approved in the USA and Europe as a treatment for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. Additionally, it is being developed in the USA as a potential treatment for cGvHD.

DCC-3116 (inlexisertib) (oral)

DCC-3116, a ULK inhibitor, is being developed in combination with ripretinib for the potential treatment of solid tumor in the USA.

DCC-3009 (oral)

DCC-3009, a pan-KIT inhibitor, is being developed in the USA for the potential treatment of gastrointestinal stromal tumor.

ONO-8531 (povetacicept) (subcutaneous injection)

ONO-8531, BAFF/APRIL dual antagonist, is being developed for the treatment of multiple serious B-cell mediated diseases, including IgA nephropathy and primary membranous nephropathy.

ONO-5532 (Gel-One) (intra-articular injection)

ONO-5532 is an intra-articular injection containing cross-linked hyaluronic acid as its active ingredient. It has been marketed overseas since 2012 under the names “Gel-One®” in the United States and “HyLink®” in Taiwan and Italy. In Japan, it is being developed for the treatment of knee osteoarthritis and hip osteoarthritis.

DCC-2812 (oral)

DCC-2812, a GCN2 activation, is being developed for the treatment of renal cell carcinoma, urothelial carcinoma, and castration-resistant prostate cancer.

ONO-7429 (Injection)

ONO-7429, an anti-L1CAM ADC, is being developed for the treatment of solid tumor.

ONO-2416 (oral)

ONO-2416, an in-house drug, is being developed for the treatment of psychiatric disorder.

ONO-3310 (oral)

ONO-3310, an in-house drug, is being developed for the treatment of kidney disease.

ONO-6414 (oral)

ONO-6414, an in-house drug, is being developed for the treatment of autoimmune disease.